Laddar...
Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer
BACKGROUND: The clinical benefit of gemcitabine, the standard systemic therapy of pancreatic cancer (PaCa), remains modest as a result of high chemoresistance. The proteasome inhibitor bortezomib has antitumour activity against PaCa in vitro and in vivo. We examined the antitumour activity of combin...
Sparad:
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Blackwell Publishing Ltd
2009
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2785956/ https://ncbi.nlm.nih.gov/pubmed/20495713 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1477-2574.2009.00109.x |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|